MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-31-2024
Syros Pharmaceuticals Retained Earnings 2011-2026 | SYRS
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Syros Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -723 M | -558 M | -464 M | -377 M | -293 M | -218 M | -155 M | -101 M | -53.5 M | -23.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -23.7 M | -723 M | -297 M |
Quarterly Retained Earnings Syros Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -756 M | -750 M | -727 M | -723 M | -658 M | -618 M | -582 M | -558 M | -553 M | -523 M | -489 M | -464 M | -440 M | -414 M | -391 M | -377 M | -377 M | -377 M | -377 M | -293 M | -293 M | -293 M | -293 M | -218 M | -218 M | -218 M | -218 M | -155 M | -155 M | -155 M | -155 M | -101 M | -101 M | -101 M | -101 M | -53.5 M | -53.5 M | -53.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -53.5 M | -756 M | -352 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-861 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Akebia Therapeutics
AKBA
|
-1.68 B | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-978 M | - | - | $ 3.45 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Codiak BioSciences
CDAK
|
-325 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
-572 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Checkpoint Therapeutics
CKPT
|
-371 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.81 B | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Celsion Corporation
CLSN
|
-421 M | - | -6.63 % | $ 13.9 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Chimerix
CMRX
|
-796 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-349 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-265 M | $ 3.88 | 2.11 % | $ 261 B | Britain |